Pancreatic Cancer Research

ResearcherNational Taiwan UniversityNo recent work listed

Chiun Hsu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1122-0055; OpenAlex author ID A5074026718. Sources: ClinicalTrials.gov.

Their work

Papers
6
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: 1 paper

Papers 6

  1. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.870406↗
  2. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Co-author DOI 10.1016/j.ejca.2019.10.023↗
  3. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Co-author DOI 10.1016/j.jfma.2019.01.015↗
  4. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i32.7275↗
  5. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Co-author DOI 10.1038/bjc.2014.494↗
  6. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Co-author DOI 10.1159/000330817↗

Trials 1

  1. A Study of Locally Advanced Pancreatic Cancer Principal investigator NCT01063192↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sung‐Hsin Kuo · 4 shared papers, 2011–2022 · strength 0.40
  2. Shih‐Hung Yang · 4 shared papers, 2011–2022 · strength 0.40
  3. Yu‐Wen Tien · 3 shared papers, 2011–2020 · strength 0.21
  4. Ann‐Lii Cheng · 3 shared papers, 2011–2020 · strength 0.21
  5. Bang‐Bin Chen · 1 shared paper, 2022 · strength 0.19
  6. Li‐Yuan Bai · 1 shared paper, 2022 · strength 0.19
  7. Jhe‐Cyuan Guo · 2 shared papers, 2016–2020 · strength 0.18
  8. Kun‐Huei Yeh · 2 shared papers, 2016–2020 · strength 0.18
  9. Yulin Lin · 1 shared paper, 2020 · strength 0.11
  10. Nai‐Jung Chiang · 1 shared paper, 2020 · strength 0.11
  11. Jen‐Shi Chen · 1 shared paper, 2020 · strength 0.11
  12. Kelvin K. Tsai · 1 shared paper, 2020 · strength 0.11
  13. Shih‐Hung Yang · 1 shared paper, 2020 · strength 0.11
  14. Li‐Tzong Chen · 1 shared paper, 2020 · strength 0.11
  15. Yan‐Shen Shan · 1 shared paper, 2020 · strength 0.11
  16. Chih‐Hung Hsu · 2 shared papers, 2011–2016 · strength 0.09
  17. Hsu Wu · 1 shared paper, 2016 · strength 0.06
  18. Ting‐Chun Kuo · 1 shared paper, 2016 · strength 0.06
  19. Pin-Wen Lin · 1 shared trial, 2009 · strength 0.05
  20. Yen-Shen Shen · 1 shared trial, 2009 · strength 0.05
  21. J-L Van Laethem · 1 shared paper, 2014 · strength 0.03
  22. Giuseppe Aprile · 1 shared paper, 2014 · strength 0.03
  23. Tudor–Eliade Ciuleanu · 1 shared paper, 2014 · strength 0.03
  24. Salomon Marcello Stemmer · 1 shared paper, 2014 · strength 0.03
  25. Malcolm J. Moore · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.